Provectus Biopharmaceuticals, Inc.
PVCT · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $50,419 | $40,273 | $45,429 | $22,452 |
| - Cash | $307 | $77 | $22 | $683 |
| + Debt | $3,185 | $3,026 | $2,229 | $1,744 |
| Enterprise Value | $53,297 | $43,222 | $47,636 | $23,513 |
| Revenue | $617 | $558 | $989 | $0 |
| % Growth | 10.7% | -43.6% | – | – |
| Gross Profit | $610 | -$1,142 | $925 | -$94 |
| % Margin | 98.8% | -204.8% | 93.6% | – |
| EBITDA | -$4,525 | -$2,892 | -$3,364 | -$4,623 |
| % Margin | -733.2% | -518.5% | -340.1% | – |
| Net Income | -$4,733 | -$3,102 | -$3,554 | -$5,540 |
| % Margin | -766.9% | -556.2% | -359.3% | – |
| EPS Diluted | -0.011 | -0.007 | -0.009 | -0.016 |
| % Growth | -52.7% | 12.9% | 46.5% | – |
| Operating Cash Flow | -$3,284 | -$2,572 | -$3,041 | -$1,013 |
| Capital Expenditures | $0 | -$0 | $0 | $0 |
| Free Cash Flow | -$3,284 | -$2,572 | -$3,041 | -$1,013 |